<p>Comparative Effect Of Curcumin Versus Liposomal Curcumin On Systemic Pro-Inflammatory Cytokines Profile, MCP-1 And RANTES In Experimental Diabetes Mellitus</p>

Abstract

PurposeAnti-inflammatory proprieties of curcumin were proved to be useful in various diseases, including diabetes mellitus. The aim of this study was to assess the anti-inflammatory comparative effect of curcumin solution with liposomal curcumin formula, regarding the improvement of serum levels of TNF-α (tumor necrosis factor-alpha), IL-6 (interleukin), IL-1α, IL-1β, MCP-1 (monocyte chemoattractant protein-1) and RANTES in experimental diabetes, induced by streptozotocin (STZ), in rats.Materials and methodsSix groups of 7 rats were investigated regarding the effect of i.p. (intraperitoneal) administration of two concentrations of curcumin solution (CC1 and CC2) and two concentrations of liposomal curcumin (LCC1 and LCC2): group 1 – control group with i.p. administration of 1 mL saline solution, group 2 – i.p. STZ administration (60mg/kg bw, bw=body weight), group 3 – STZ+CC1 administration, group 4 – STZ+CC2 administration, group 5 – STZ+ LCC1 administration and group 6 – STZ+ LCC2 administration. The concentrations of curcumin formulas were 1 mg/0.1 kg bw for CC1 and LCC1 and 2 mg/0.1 kg bw for CC2 and LCC2, respectively. Serum levels of C-peptide (as an indicator of pancreatic function) and TNF-α, IL-6, IL-1α, IL-1β, MCP-1, and RANTES (as biomarkers for systemic inflammation) were assessed for each group.ResultsThe plasma level of C-peptide showed significant improvements when LCC was administrated, with better results for LCC2 when compared to LCC1 (P<0.003). LCC2 pretreatment proved to be more efficient in reducing the level of TNF-α (P<0.003) and RANTES (P<0.003) than CC2 pretreatment. Upon comparing LCC2 with LCC1 formulas, the differences were significant for TNF-α (P=0.004), IL-1β (P=0.022), and RANTES (P=0.003) levels.ConclusionLiposomal curcumin in a dose of 2 mg/0.1 kg bw proved to have an optimum therapeutic effect as a pretreatment in DM induced by STZ. This result can constitute a base for clinical studies for curcumin efficiency as adjuvant therapy in type 1 DM.

Tuftsin-Bearing Liposomes Co-Encapsulated with Doxorubicin and Curcumin Efficiently Inhibit EAC Tumor Growth in Mice

“…Furthermore, in this study liposomes were used as nanocarriers, owing to its enhanced stability, bioavailability, and shelf life for sensitive ingredients as they are assembled from phospholipid bilayers similar to cell membranes and their biphasic character making them suitable for being carriers for both hydrophilic (in the central aqueous compartment) and hydrophobic (in lipid bilayers) compound. 26,27 Tuftsin a tetrapeptide (Thr-Lys-Pro-Arg) stimulates immunomodulatory effects by binding specifically to macrophages, monocytes, and polymorphonuclear leukocytes (PMN). 28 Many studies have reported the anti-tumor efficacy of tuftsin in animal models.…”

The Effect of Nano-Epigallocatechin-Gallate on Oxidative Stress and Matrix Metalloproteinases in Experimental Diabetes Mellitus

“…Each medication was dissolved in saline solution (0.9% sodium chloride) and the volume administrated i.p. was 1 mL [19]. The following doses were used: STZ-60 mg/100 g body weight (b.w.)…”

“…One of the most used experimental models for testing various therapies addressing type 1 DM is based on STZ administration. STZ induces type 1 DM, with destruction of pancreatic beta cells and associated insulin deficiency, as a result of its cytotoxic effect, mediated by increased synthesis of reactive oxygen species (ROS) and subsequent inflammation [18][19][20]. A protective effect of EGCG on pancreatic beta cells has been already demonstrated in experimental studies [21]; meanwhile, oral chronic administration of EGCG proved to have hypoglycemic and hypolipidemic effects and to reduce oxidative stress in streptozotocin-diabetic rats [22].…”

Molecular Insight into the Anti-Inflammatory Effects of the Curcumin Ester Prodrug Curcumin Diglutaric Acid In Vitro and In Vivo

“…One study reported that oral administration of curcumin inhibited edema induced by carrageenan at doses of 50–200 mg/kg in mice [ 6 ]. Moreover, curcumin has demonstrated beneficial effects in various diseases associated with inflammation, such as diabetes mellitus [ 7 ], myocardial infarction [ 8 ], and migraine [ 9 ]. While curcumin has many advantageous pharmacological properties, its development as a therapeutic agent is limited on account of its low aqueous solubility, poor absorption, and metabolic instability, which lead to poor oral bioavailability.…”